{"id":"W2810342468","doi":"10.1001/jamaoncol.2018.1812","title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Bausch Health (Canada); London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Metastatic breast cancer; Taxane; Internal medicine; Adverse effect; Breast cancer; Pharmacokinetics; Oncology; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Capecitabine; Gastroenterology; Pharmacology; Progressive disease; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007274245,0.0003389828,0.001042166,0.0002201019,0.0001989686,0.0004638782,0.0002761882,0.0003536449,0.001296853],"category_scores_gemma":[0.000639828,0.0001707755,0.0004240183,0.0002380192,0.0002435429,0.0003813752,0.000176749,0.0006624199,0.0002076485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004247307,"about_ca_system_score_gemma":0.0006637416,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005640147,"about_ca_topic_score_gemma":0.002191206,"domain_scores_codex":[0.9997682,0.0001081861,0.00002362996,0.00003372944,0.00003453482,0.0000317604],"domain_scores_gemma":[0.9997585,0.00004530627,0.00008257486,0.000015644,0.00001752063,0.00008043334],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5652175,0.03021937,0.0373988,0.001947632,0.002260742,0.0004110717,0.0002782978,0.00372422,0.07317595,0.0002957855,0.003549868,0.2815208],"study_design_scores_gemma":[0.2752253,0.6127869,0.0803413,0.0001876172,0.001446535,0.001200127,0.0001409694,0.004739548,0.01673384,0.0002169507,0.006937268,0.0000435667],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967315,0.002201126,0.00008968508,0.00008574508,0.00002460288,0.0002163259,0.00009544296,0.00001143388,0.00054416],"genre_scores_gemma":[0.9978653,0.001095452,0.0002340297,0.00009883505,0.00004668237,0.000143363,0.000186779,0.000002378092,0.0003271955],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001296853,"threshold_uncertainty_score":0.004338384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02518294945205386,"score_gpt":0.3936798830373113,"score_spread":0.3684969335852575,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}